Johnson & Johnson

Name

Johnson & Johnson

Legal name

Johnson & Johnson

Website

https://jnj.com

Company type

Public

Founded year

1886

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Medical Devices

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Pharmaceutical drugs
• Medical devices
• Oncology treatments
• Immunology therapies
• Cardiovascular devices

Headquarters

HQ city

New Brunswick

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Innovative Medicine (Pharmaceuticals): Revenue from prescription pharmaceuticals including immunology drugs (Tremfya, Stelara), oncology treatments (Darzalex, Carvykti, Tecvayli, Talvey), neuroscience, and cardiovascular medications. FY2025 revenue of $94.2 billion with 6% growth, targeting $100 billion+ in 2026.
2. MedTech (Medical Devices): Revenue from medical technologies including cardiovascular implants (Abiomed, V-Wave), vision care (Acuvue contact lenses), surgical robotics, and ablation technologies. Part of diversified healthcare portfolio.
3. US Manufacturing Investment Services: Johnson & Johnson announced $55 billion investment in U.S. manufacturing, R&D and technology through early 2029, including biologics manufacturing in North Carolina and contact lens production in Florida.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Johnson & Johnson develops, manufactures, and commercializes prescription pharmaceuticals and medical devices through two operating segments: Innovative Medicine (oncology, immunology, neuroscience, and cardiovascular drugs) and MedTech (cardiovascular implants, surgical robotics, electrophysiology ablation systems, and vision-care products such as Acuvue contact lenses). The portfolio is anchored by 28 product platforms each generating over $1 billion in annual revenue and targets first-in-class therapies for serious diseases including multiple myeloma, generalized myasthenia gravis, and heart failure.

Product overview

Johnson & Johnson's product portfolio spans two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The Innovative Medicine segment includes oncology drugs such as DARZALEX, TECVAYLI, TALVEY, and CARVYKTI for multiple myeloma; immunology treatments like TREMFYA and IMAAVY for autoimmune conditions; and neuroscience drugs. The MedTech segment encompasses cardiovascular devices (Abiomed Impella pumps, V-Wave shunt), surgical robotics (Velys system), electrophysiology platforms (THERMOCOOL SMARTTOUCH ablation), and vision care products (ACUVUE contact lenses). The company is pursuing a strategy to become the world's leading oncology company by 2030 with a goal of $50 billion in oncology sales, while expanding its medical device portfolio through acquisitions and organic innovation.

Differentiator

Problem solved

Functional benefit

Brands

• ACUVUE: Contact lens brand for vision correction
• DARZALEX
• TALVEY
• TECVAYLI
• TREMFYA
• CARVYKTI
• IMAAVY
• Velys

Products and services

• IMAAVY (nipocalimab-aahu) FcRn antagonist antibody therapy indicated for the treatment of generalized myasthenia gravis (gMG); reduces pathogenic IgG autoantibodies and is sold to hospitals and prescribing neurologists.

Quantifiable outcome

• TALVEY plus DARZALEX FASPRO achieved 72% reduction in risk of disease progression or death and up to 53% reduction in mortality risk versus standard therapy in multiple myeloma patients
• +6 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• NanobiotixcoreStrategic or Co-development Partner · 25 June 2026Johnson & Johnson's Janssen unit partners with Nanobiotix for NBTXR3/JNJ-1900 radioenhancer platform using functionalized hafnium oxide nanoparticles. Potential $2.6 billion in milestones and tiered double-digit royalties. Phase 3 NANORAY-312 pivotal trial underway for multiple solid tumor applications including lung cancer.
• McLaren Bay Region HospitalminorStrategic or Co-development Partner · 15 June 2026First patient treated in SKYWARD IDE clinical program evaluating Shockwave SkyRunner Carotid IVL system at McLaren Bay Region Hospital in Michigan.
• Bristol Myers Squibb (Milvexian partnership)minorStrategic or Co-development Partner · 1 June 2026Collaboration with BMS for development of Milvexian, a Factor XIa inhibitor, for atrial fibrillation. Milvexian is being developed to address stroke prevention amid BMS's expected patent cliff on Eliquis.
• Protagonist TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 1 March 2026J&J licensed ICOTYDE (icotrokinra) from Protagonist for psoriasis treatment, triggering $50 million milestone payment with potential for up to $580 million additional milestones and 6-10% tiered royalties on projected $4 billion annual sales.
• Poolbeg PharmaminorStrategic or Co-development Partner · 1 January 2026Clinical trial collaboration testing Poolbeg's POLB 001 drug with J&J's teclistamab (Tecvayli) to prevent cytokine release syndrome in cancer immunotherapy patients. Trial at six NHS hospitals in Britain with 30 patients.
• LuNGS AllianceminorStrategic or Co-development Partner · 1 March 2025Collaboration for lung cancer diagnostics including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche, Tata Capital, and startup 4baseCare. Provided free NGS tests to over 6,600 lung cancer patients across 700 cities since March 2025.
• Legend BiotechcoreStrategic or Co-development Partner · 1 January 2024Partnership for CARVYKTI (ciltacabtagene autoleucel) CAR-T cell therapy for multiple myeloma. Generated $1 billion in CAR-T revenue for Legend Biotech. J&J holds significant stake in Legend Biotech.

Scale indicators18 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Pfizer: One of J&J's closest direct peers as a global diversified pharmaceutical company with parallel oncology, immunology, neuroscience, and vaccine portfolios. Pfizer's elranatamab bispecific directly competes in multiple myeloma and competes with J&J in cardiology and rare disease.
• Merck & Co. Top-tier global pharmaceutical competitor with overlapping oncology (Keytruda) and vaccine franchises, and a similar scale profile (>$60B revenue). Direct peer in immuno-oncology and competes with J&J in immunology and hospital specialty channels.
• Roche: Swiss-based diversified pharmaceutical and diagnostics leader with overlapping oncology (multiple myeloma via CD38 bispecifics), immunology, neuroscience, and a large MedTech-style diagnostics franchise. Comparable size and global footprint.
• Novartis: Global pharmaceutical peer with overlapping oncology, immunology (Cosentyx), cardiovascular (Entresto), and neuroscience franchises. Similar post-spin-off profile (Sandoz spun out) and active in bispecific antibody development competing with J&J's Talvey/Tecvayli.
• Bristol Myers Squibb: Direct oncology and immunology peer (Revlimid, Pomalyst in multiple myeloma; Opdivo in oncology; Eliquis in cardiovascular). BMS is also J&J's Milvexian co-development partner, creating a hybrid competitor/partner dynamic across cardiology and hematology.
• AstraZeneca: Global biopharma peer with major oncology, cardiovascular, and respiratory franchises, and an active acquirer in bispecifics and ADCs that compete with J&J's pipeline. Member of the LuNGS Alliance alongside J&J.
• Eli Lilly: Top-tier global pharmaceutical peer with strong oncology, immunology, neuroscience (Alzheimer's), and diabetes franchises. Direct competitor in immunology (Taltz vs Tremfya) and rapidly scaling in oncology and obesity; also a LuNGS Alliance partner.
• AbbVie: Specialty pharmaceutical peer with major immunology (Humira/Skyrizi/Rinvoq), neuroscience (Vraylar), and oncology franchises. Comparable scale, post-Humira growth narrative, and overlapping bispecific/ADC strategy.
• Sanofi: Global pharmaceutical peer with parallel immunology (Dupixent), rare disease, neurology, and vaccine franchises. Competes with J&J in immunology and is a comparable-scale European-headquartered diversified pharma.
• Amgen: Biopharmaceutical peer with overlapping oncology, inflammation, and cardiovascular franchises, including Tezspire and Imdelltra competing with J&J's bispecific strategy. Comparable post-acquisition growth profile (Horizon) and biologics manufacturing scale.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat7 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/jnjnews
• Facebookfacebook.com/jnj

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A52 records

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson